TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$39.41
-0.80 (-1.99%)
âŧ
5d:
-5.04%
30d:
-2.01%
90d:
+26.8%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 03, 2026
9d
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TEVA is fairly priced but lacks strong directional signals. At 4.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TEVA is fairly priced but lacks strong directional signals. At 4.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$67.35
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$41.82
5.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $39.41, which is considered slightly low relative to its 30-day fair value range of $39.00 to $40.75. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.8) compared to its historical average (11.2). At these levels, the market is pricing in 4.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TEVA is in a strong uptrend. The price is currently testing key support at $39.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TEVA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $47.58 (+20.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TEVA is in a strong uptrend. The price is currently testing key support at $39.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TEVA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $47.58 (+20.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$39.00 -
$40.75
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.7% below Wall St target ($47.58)
- NEUTRAL: Market pricing in 4.5% annual earnings growth - fairly valued
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$39.00 -
$40.75
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$39.11
Resistance Level
$41.88
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.76
Wall Street Target
$47.58
(+20.7%)
Revenue Growth (YoY)
-0.8%
Earnings Growth (YoY)
72.2%
Profit Margin
4.1%
Valuation Premium vs History
+4.5% premium
PE vs Historical
12.8 vs 11.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.5%
(market-implied from PE analysis)
1-Year Target
$41.18
(+5%)
2-Year Target
$43.04
(+9%)
3-Year Target
$44.97
(+14%)
3-Yr Target (if PE normalizes)
(PE: 13â11)
PE COMPRESSION
$39.47
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 46.5%)
$192.82
(+389%)
Base:
(SPY PE: 12.8, Growth: 46.5%)
$123.92
(+214%)
Bear:
(PE: 10.8, Growth: 46.5%)
$105.33
(+167%)
đ
Valuation based on Current Earnings
Forward PE: 7.05 | Forward EPS (Implied): $5.59
Bull Case
$47.59
(+21%)
Analyst growth 15.0%, PE expands to 7.4
Base Case
$39.41
(0%)
Market implied 0.0%, PE stable at 7.1
Bear Case
$30.15
(-24%)
Severe decline -15.0%, PE contracts to 6.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 8:55 PM ET
Data refreshes hourly during market hours. Next update: 9:55 PM
Data refreshes hourly during market hours. Next update: 9:55 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
